GLAND PHARMA
(NSE: GLAND)
Business:
Gland Pharma is a global pharmaceutical company focused on injectables, complex formulations and CDMOStrong presence across the US, Europe and other regulated marketsThe business is increasingly moving towards higher value CDMO and complex injectable opportunitiesQ1 FY27 Performance š
Revenue: ā¹1,800 Cr | +20% YoYEBITDA: ā¹493 Cr | +34% YoYAdjusted EBITDA Margin: 28% vs 25% YoYPAT: ā¹317 Cr | +47% YoYCDMO revenue: ā¹892 Cr | +20% YoYUS revenue grew 32% YoYBig Growth Opportunity š
CDMO contributed around 50% of Q1 revenueCompany secured multiple new CDMO contracts across complex injectables, peptides and drug delivery platformsA new strategic agreement covers 55 sterile injectable SKUs across three manufacturing sitesOnce commercialised, the agreement has an estimated annual revenue potential of US$90M to US$100MMeaningful revenue contribution from this particular agreement is expected from 2029.Key Positives š¢
Strong double digit revenue and profit growthImproving capacity utilisation supporting operating leverageHigh value complex injectables provide better long term growth potentialCenexi integration is strengthening the CDMO platformā¹2,000 Cr capex program is underway for additional vial, ophthalmic, BFS and liposomal capacitiesRecent USFDA inspection at the VSEZ sterile oncology formulations and API facility concluded in September 2026.What Iām Watching ā ļø
Large CDMO opportunities have long development and commercialisation timelinesCapex execution and return on invested capital need monitoringBusiness remains significantly exposed to regulated markets, particularly the USPromoter Fosun has recently reduced its stake, which can remain an overhang on the stock in the near term.Overall View:
Gland Pharma has started FY27 strongly, with 20% revenue growth and 47% PAT growth.
The bigger story for me is the increasing contribution from CDMO, complex injectables and higher value products. If the company executes its capacity expansion well, the business could have multiple growth drivers over the next few years.
The key monitorables are CDMO order conversion, margin sustainability, capacity utilisation and new product launches.
Technical Setup:
š Refer to the chart for my technical levels, support/resistance zones and price action view.
Disclaimer: Educational content only. Not investment advice. Please do your own research.
